Gemin X Biotechnologies

Gemin X Biotechnologies Inc. discovers and develops small molecule cancer therapeutics based on the regulation of apoptosis. The company develops small molecules targeting cancer pathways, including modulators of cancer initiation and progression. Its products include GX15-070, a small molecule indole dipyrrole drug compound and a pan-inhibitor of Bcl-2 protein; oral GX15-070, an oral formulation of GX15-070; and GMX1777, a water-soluble prodrug of GMX1778, which has demonstrated anticancer activity in preclinical in vitro and in vivo studies. Gemin X Biotechnologies Inc. also conducts research programs in the fields of telomere capping and p53-independent mechanisms.